HRT Reports 'Remarkable Achievement' In OTC Naloxone Phase 1 Clinical Trial Results

Harm Reduction Therapeutics CEO Michael Hufford says non-profit is “rapidly moving forward” with OTC naloxone NDA.

Source: Alamy (Alamy Stock Photo)

Phase 1 clinical trial results indicate Harm Reduction Therapeutics LLC's proposed RiVive OTC naloxone nasal spray has biological results comparable to Rx intramuscular naloxone available in the US.

The trial of the 3-mg nasal spray, identified in HRT's study as HRT001, which delivers an atomized form of 0.1-mL...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health